D. E. Shaw & Co., Inc. Bio Atla, Inc. Transaction History

D. E. Shaw & Co., Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $183,735 - $464,084	-86,261 Reduced 28.58%	215,612 $614,000
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $1.19 Million - $5.11 Million	272,107 Added 914.15%	301,873 $1.51 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $565,554 - $921,257	29,766 New	29,766 $584,000

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.